OleanderPhoenix enters into contract with Quintiles, Inc. to act as Clinical Research Organization for “An Open Label Phase I Trial of PBI-05204 in Advanced Cancer Patients” to be conducted at M. D. Anderson Cancer Center. Posted on June 2007June 2022 by Carlos Torres 06 Jun Phoenix Biotechnology, Inc. executes a share exchange agreement with Nerium Biotechnology, Inc. by which Nerium Biotechnology acquires all the Latin American operations of Phoenix. USFDA approves Phoenix IND 73,624 application to conduct a Phase I Trial with PBI-05204, a patented supercritical extract of Nerium oleander, in patients with advanced cancer.
